Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2389-2400

  Kim, Dong Wook ^a   Walker, Robert L ^a   Meltzer, Paul S ^a   Cheng, Sheue yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION PROFILING; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; TUMOR INVASION; UPREGULATION; WILD TYPE;

ANIMALS; CARCINOGENESIS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84885118876     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt175     Document Type: Article

References (74)

1. Siegel, R. et al. (2012) Cancer treatment and survivorship statistics, 2012. CA. Cancer J. Clin., 62, 220-241.
2. Handkiewicz-Junak, D. et al. (2010) Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol. Cell. Endocrinol., 322, 8-28.
3. Xing, M. (2008) Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol. Clin. North Am., 41, 1135-46, ix.
4. Kaneshige, M. et al. (2000) Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl Acad. Sci. USA, 97, 13209-13214.
5. Parrilla, R. et al. (1991) Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J. Clin. Invest., 88, 2123-2130.
6. Suzuki, H. et al. (2002) Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 12, 963-969.
7. Furuya, F. et al. (2006) Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc. Natl Acad. Sci. USA, 103, 1780-1785.
8. Ringel, M.D. et al. (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res., 61, 6105-6111.
9. Lu, C. et al. (2010) Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology, 151, 1929-1939.
10. Ying, H. et al. (2006) Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J. Clin. Invest., 116, 2972-2984.
11. Kim, C.S. et al. (2007) The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis, 28, 932-939.
12. Guigon, C.J. et al. (2008) Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol. Cell. Biol., 28, 4598-4608.
13. Chen, Y. et al. (1997) Ratio-based decisions and the quantitative analysis of cDNA microarray images. J. Biomed. Opt., 2, 364-374.
14. Khan, J. et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med., 7, 673-679.
15. Nimmakayalu, M. et al. (2000) Simple method for preparation of fluor/hapten-labeled dUTP. Biotechniques, 28, 518-522.
16. Guigon, C.J. et al. (2010) Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology, 151, 5528-5536.
17. Kim, D.W. et al. (2012) Thyroid hormone receptor β suppresses SV40-mediated tumorigenesis via novel nongenomic actions. Am. J. Cancer Res., 2, 606-619.
18. Kebebew, E. et al. (2005) Diagnostic and prognostic value of angiogenesismodulating genes in malignant thyroid neoplasms. Surgery, 138, 1102-9; discussion 1109.
19. Vasko, V. et al. (2007) Gene expression and functional evidence of epithelial- to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl Acad. Sci. USA, 104, 2803-2808.
20. Yamamoto, Y. et al. (1992) An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types. Cancer, 70, 2326-2333.
21. Corvi, R. et al. (2000) RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. Oncogene, 19, 4236-4242.
22. Costa, P. et al. (2006) Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study. Endocr. Pathol., 17, 377-386.
23. Anania, M.C. et al. (2011) TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene, 30, 3011-3023.
24. Kubiczkova, L. et al. (2012) TGF-β - an excellent servant but a bad master. J. Transl. Med., 10, 183.
25. Skonier, J. et al. (1992) cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol., 11, 511-522.
26. de Graauw, M. et al. (2010) Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc. Natl Acad. Sci. USA, 107, 6340-6345.
27. Isono, M. et al. (2002) Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem. Biophys. Res. Commun., 296, 1356-1365.
28. Hallatschek, W. et al. (2004) Inhibition of hepatic transcriptional induction of lipopolysaccharide-binding protein by transforming-growth-factor beta 1. Eur. J. Immunol., 34, 1441-1450.
29. Okazaki, R. et al. (1995) Transforming growth factor-beta and forskolin increase all classes of insulin-like growth factor-I transcripts in normal human osteoblast-like cells. Biochem. Biophys. Res. Commun., 207, 963-970.
30. Rogel, M.R. et al. (2011) Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. FASEB J., 25, 3873-3883.
31. Jiang, Y. et al. (2005) Transforming growth factor-beta1 regulation of laminin gamma1 and fibronectin expression and survival of mouse mesangial cells. Mol. Cell. Biochem., 278, 165-175.
32. Grande, J. et al. (1993) Transforming growth factor-beta 1 induces collagen IV gene expression in NIH-3T3 cells. Lab. Invest., 69, 387-395.
33. Calonge, M.J. et al. (2004) Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor-beta. J. Biol. Chem., 279, 23759-23765.
34. Sayeed, A. et al. (2010) Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Dis., 1, e53.
35. Heegaard, A.M. et al. (2004) Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors. J. Cell. Biochem., 93, 463-475.
36. Smeland, E.B. et al. (1987) Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp. Cell Res., 171, 213-222.
37. Kenyon, N.J. et al. (2003) TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax, 58, 772-777.
38. Norris, A. et al. (2012) AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene. http://dx.doi.org/10.1038/onc.2012.394 (3 September 2012, date last accessed).
39. Ghafoori, P. et al. (2009) Increased IkappaB alpha expression is essential for the tolerogenic property of TGF-beta-exposed APCs. FASEB J., 23, 2226-2234.
40. Nakamura, H. et al. (2005) Transforming growth factor-beta1 induces LMO7 while enhancing the invasiveness of rat ascites hepatoma cells. Cancer Lett., 220, 95-99.
41. Wang, B. et al. (2010) TGFbeta-mediated upregulation of hepatic miR- 181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene, 29, 1787-1797.
42. Eisenwort, G. et al. (2011) Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-β1-dependent human epidermal Langerhans cells. J. Invest. Dermatol., 131, 2049-2057.
43. Huang, W. et al. (2011) Enhanced expression of tissue inhibitor of metalloproteinases- 4 gene in human osteoarthritic synovial membranes and its differential regulation by cytokines in chondrocytes. Open Rheumatol. J., 5, 81-87.
44. Lu, Z. et al. (2001) Transcriptional regulation of the lung fatty acid synthase gene by glucocorticoid, thyroid hormone and transforming growth factorbeta 1. Biochim. Biophys. Acta, 1532, 213-222.
45. Sharma, V. et al. (2011) Enhancement of TGF-β signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer. Cancer Res., 71, 6438-6449.
46. Yan, Z. et al. (2001) Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. J. Biol. Chem., 276, 1555-1563.
47. Park, B.J. et al. (2000) Mitogenic conversion of transforming growth factorbeta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res., 60, 3031-3038.
48. Jonson, T. et al. (2001) Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. Int. J. Oncol., 19, 71-81.
49. Heldin, C.H. et al. (2012) Regulation of EMT by TGFβ in cancer. FEBS Lett., 586, 1959-1970.
50. Obara, M. et al. (2010) The third type III module of human fibronectin mediates cell adhesion and migration. J. Biochem., 147, 327-335.
51. McInroy, L. et al. (2007) Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem. Biophys. Res. Commun., 360, 109-114.
52. Marneros, A.G. et al. (2005) Physiological role of collagen XVIII and endostatin. FASEB J., 19, 716-728.
53. Gu, Y.C. et al. (2003) Laminin isoform-specific promotion of adhesion and migration of human bone marrow progenitor cells. Blood, 101, 877-885.
54. Olivero, D.K. et al. (1993) Type IV collagen, laminin, and fibronectin promote the adhesion and migration of rabbit lens epithelial cells in vitro. Invest. Ophthalmol. Vis. Sci., 34, 2825-2834.
55. Lisman, T. et al. (2006) A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood, 108, 3753-3756.
56. Tummalapalli, C.M. et al. (2001) Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J. Cell. Biochem., 80, 512-521.
57. Teng, Y. et al. (2007) Transcriptional regulation of epithelial-mesenchymal transition. J. Clin. Invest., 117, 304-306.
58. Scheumman, G.F. et al. (1995) Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J. Clin. Endocrinol. Metab., 80, 2168-2172.
59. Sherman-Baust, C.A. et al. (2003) Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell, 3, 377-386.
60. Tang, L. et al. (2006) Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin. Cancer Res., 12, 3716-3722.
61. Shintani, Y. et al. (2008) Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am. J. Respir. Cell Mol. Biol., 38, 95-104.
62. Espinosa Neira, R. et al. (2012) Native type IV collagen induces an epithelial to mesenchymal transition-like process in mammary epithelial cells MCF10A. Int. J. Biochem. Cell Biol., 44, 2194-2203.
63. De Arcangelis, A. et al. (2001) Overexpression of laminin alpha1 chain in colonic cancer cells induces an increase in tumor growth. Int. J. Cancer, 94, 44-53.
64. Fujita, M. et al. (2005) Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res., 7, R411-R421.
65. Yang, J. et al. (2009) Lipocalin 2 promotes breast cancer progression. Proc. Natl Acad. Sci. USA, 106, 3913-3918.
66. Walsh, L.A. et al. (2011) IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition. Cell Commun. Signal., 9, 10.
67. Bergamaschi, A. et al. (2008) CAMK1D amplification implicated in epithelial- mesenchymal transition in basal-like breast cancer. Mol. Oncol., 2, 327-339.
68. Perez-Pinera, P. et al. (2006) Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition. Proc. Natl Acad. Sci. USA, 103, 17795-17800.
69. Zeisberg, M. et al. (2009) Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest., 119, 1429-1437.
70. Grünert, S. et al. (2003) Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol., 4, 657-665.
71. Kim, W.G. et al. (2012) SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin. Cancer Res., 18, 1281-1290.
72. Nagathihalli, N.S. et al. (2012) Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front. Biosci., 17, 2059-2069.
73. Cicchini, C. et al. (2008) TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp. Cell Res., 314, 143-152.
74. Avizienyte, E. et al. (2004) Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol. Biol. Cell, 15, 2794-2803.